Iceutica Operations Drug Patent Portfolio
Iceutica Operations owns 1 orange book drug protected by 3 US patents Given below is the list of Iceutica Operations's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9649318 | Formulation of meloxicam | 31 Mar, 2035 | Active |
| US9808468 | Formulation of meloxicam | 31 Mar, 2035 | Active |
| US9526734 | Formulation of meloxicam | 31 Mar, 2033 | Active |
Latest Legal Activities on Iceutica Operations's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Iceutica Operations.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 07 May, 2021 | US9808468 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 16 Nov, 2020 | US9649318 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 16 Oct, 2020 | US9649318 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 29 Jun, 2020 | US9526734 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 22 May, 2020 | US9526734 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 07 Nov, 2017 | US9808468 |
|
Recordation of Patent Grant Mailed
Critical
| 07 Nov, 2017 | US9808468 |
|
Email Notification
Critical
| 19 Oct, 2017 | US9808468 |
|
Issue Notification Mailed
Critical
| 18 Oct, 2017 | US9808468 |
|
Application Is Considered Ready for Issue
Critical
| 29 Sep, 2017 | US9808468 |
| Dispatch to FDC | 29 Sep, 2017 | US9808468 |
|
Issue Fee Payment Received
Critical
| 27 Sep, 2017 | US9808468 |
| Response to Reasons for Allowance | 27 Sep, 2017 | US9808468 |
|
Issue Fee Payment Verified
Critical
| 27 Sep, 2017 | US9808468 |
|
Email Notification
Critical
| 01 Sep, 2017 | US9808468 |
Iceutica Operations's Family Patents
Iceutica Operations drugs have patent protection in a total of 16 countries. It's US patent count contributes only to 34.8% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Iceutica Operations Drug List
Given below is the complete list of Iceutica Operations's drugs and the patents protecting them.
1. Vivlodex
Vivlodex is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9649318 | Formulation of meloxicam |
31 Mar, 2035
(10 years from now)
| Active |
| US9808468 | Formulation of meloxicam |
31 Mar, 2035
(10 years from now)
| Active |
| US9526734 | Formulation of meloxicam |
31 Mar, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vivlodex's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List